Compare KLA Corp. (KLAC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs Neurocrine Biosciences Inc — how do they compare? KLA Corp. trades at $217.99 (market cap $271.18B), while Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B). The key difference: KLA Corp. is far larger — about 15.6× Neurocrine Biosciences Inc's market cap, and KLA Corp. pays a 0.44% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| KLAC | NBIX | |
|---|---|---|
Market Cap | $271.18B | $17.40B |
Sector | Technology | Health |
52-Week High | $301.71 | $180.55 |
52-Week Low | $84.39 | $123.10 |
Enterprise Value | $272.37B | $16.49B |
Dividend Yield | 0.44% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
